Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention.
Early diagnosis of prostate cancer holds tremendous promise for the effective therapy and impact on survival of prostate cancer patients. High-grade prostatic intraepithelial neoplasia (HGPIN) is generally accepted as a lesion indicative of a late pathological event in the premalignant changes leading to full development of prostate cancer. This review seeks to identify specific molecular events that may be linked directly to the molecular transition from benign prostate epithelial cells to prostate carcinoma. HGPIN is pathologically detected in a limited group of men undergoing prostate cancer screening for an elevated serum prostate-specific antigen (PSA) or abnormal digital rectal examination (DRE). Loss of apoptotic control provides a molecular basis for the contribution of specific defective steps in the pathway towards development and progression of prostate cancer. Comparative dissection of the apoptosis status and expression profile of key apoptotic regulators among foci of highly proliferative benign prostatic epithelium, PIN and prostate adenocarcinoma from adjacent areas of the same gland revealed a novel insight into the dysfunctional apoptosis events contributing to prostate carcinogenesis. The sequential and notable loss of the three critical signaling components of the apoptotic action of transforming growth factor-beta (TGF-beta), in the prostate, that is, the transmembrane receptor II (TbetaRII), the key cell cycle inhibitor p27(Kip1), as well as the protagonist downstream effector of the TGF-beta signaling mechanism, Smad4, points to their potential value to 'faithfully' characterize HGPIN, as a premalignant prostate lesion. Recent evidence on the molecular changes in apoptosis regulators contributing to HGPIN and their role as molecular markers of disease onset, as well as candidates for therapeutic targeting/chemoprevention of prostate cancer in its early stages will be discussed.
Division of Urology, Department of Surgery, University of Kentucky Medical Center, Rose Street, Lexington, KY 40536, USA.
L
L
Zeng
N
N
Kyprianou
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000473:pathology* / Q000517:prevention & control; D017209:Apoptosis; D015415:Biomarkers / Q000032:analysis*; D049109:Cell Proliferation; D002471:Cell Transformation, Neoplastic; D003937:Diagnosis, Differential; D006133:Growth Substances; D006801:Humans; D008297:Male; D010808:Physical Examination; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000032:analysis; D019048:Prostatic Intraepithelial Neoplasia / Q000175:diagnosis* / Q000473:pathology* / Q000517:prevention & control; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology* / Q000517:prevention & control; D012007:Rectum; D015398:Signal Transduction
D015415:Biomarkers; D006133:Growth Substances; D017430:Prostate-Specific Antigen